首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1917825

器官晶片市場－2026-2031年預測

Organs On Chip Market - Forecast from 2026 to 2031

出版日期: 2026年01月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計器官晶片市場將從 2025 年的 150,319,000 美元成長到 2031 年的 625,390,000 美元，複合年成長率為 26.82%。

器官晶片（OOC）市場是生物技術和生命科學工具領域的前沿細分市場，致力於開發和商業化模擬人體器官結構和功能的微型生物工程系統。器官晶片是一種微流體細胞培養裝置，通常大小與U盤相仿，其中包含活體人類細胞，這些細胞的排列旨在模擬特定器官或組織界面的關鍵生理特徵。透過整合動態機械力、流體流動和多細胞結構，這些平台旨在創建比傳統靜態細胞培養更具預測性的體外人體模型。該市場的主要驅動力是臨床前研究中對高精度、與人體相關的數據的追求。

市場擴張的驅動力來自藥物研發的迫切需求以及科學和倫理範式的轉變。其中一個關鍵促進因素是藥物發現和開發過程中對更具預測性的模型的需求日益成長。臨床試驗中候選藥物持續高失敗率（通常是由於療效不足或動物模型中未預測到的意外毒性）促使人們迫切獎勵更好的臨床前工具。晶片上（OOC）平台可望在研發早期階段提供人類特異性的藥理學和毒理學數據，從而降低研發風險。這與日益興起的個人化醫療密切相關，在個人化醫療中，可以使用患者來源的細胞在晶片上測試反應分層和個人化治療策略。此外，出於倫理方面的考慮以及減少、最佳化和替代動物試驗（3R原則）的監管壓力不斷增加，正在加速尋找有效的替代方案，使OOC技術成為科學嚴謹的候選方案。

市場技術發展軌跡以日益成長的生物複雜性和功能整合為特徵。創新正從單一器官晶片朝向互聯的多器官系統，或稱為「晶片上的人體」平台發展，旨在模擬全身藥物吸收、分佈、代謝和排泄（ADME）以及器官間的相互作用。同時，技術進步的重點在於透過整合患者來源的誘導性多功能幹細胞）、免疫系統成分以及更高級的微生物組相互作用，來提高單一晶片的生理相關性。這種從概念驗證到穩健、標準化且可重複的、可用於檢測的平台的演變，對於實現更廣泛的應用至關重要。

競爭格局和資金籌措呈現出一個充滿活力的生態系統，該系統由專業生物技術Start-Ups公司、學術衍生企業以及大型製藥企業日益成長的參與組成。合作是主導模式，製藥公司通常與OOC（體外檢測）開發商建立研究夥伴關係或授權協議，共同檢驗特定應用平台。技術提供者的成功取決於其能否展現清晰且可量化的價值，例如能否複製已知的人體藥物反應、預測臨床毒性，或與現有方法相比降低檢測時間和成本。建立標準化通訊協定並產生可靠的臨床檢驗數據，對於將探索性研究工具轉化為工業研發工作流程的整合組件至關重要。

儘管其具有變革性的潛力，但市場主流化應用仍面臨許多障礙。首要挑戰在於，如何在微觀尺度上忠實地模擬人體器官生理，這涉及技術和生物學上的複雜性。重現複雜的細胞微環境、血管分佈以及器官特異性的機械訊號傳導，仍然是一項重大的工程和生物學難題。這種複雜性直接導致了第二個主要阻礙因素：高成本。開發和運作先進的器官移植平台需要專用設備、耗材和高技能人員，而且必須透過降低後期失敗率來證明投資收益的合理性。最後，要獲得監管部門的核准以取代現有的動物模型用於安全藥理學研究，需要經歷漫長的過程，在獲得FDA和EMA等機構的核准之前，需要累積大量且令人信服的證據。

總之，晶片器官市場是一個潛力巨大、創新主導的領域，它融合了生物學、工程學和資料科學。其成長在概念上得到了藥物研發領域強勁的經濟和倫理驅動力的支持。對於業內人士而言，策略重點應體現在三個方面：透過系統檢驗黃金標準的臨床數據來建立信任；透過可擴展的生產和自動化來降低成本；以及開發使用者友好、標準化的系統，使其能夠無縫整合到現有的工業實驗室工作流程中。最終衡量成功的標準將是該技術能否提高藥物研發的可預測性，從而降低成本、加速研發進程，並為患者提供更安全、更有效的治療方法。

本報告的主要優勢：

深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

歷史資料（2021-2025 年）和預測資料（2026-2031 年）
成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
競爭對手定位、策略和市場佔有率分析
按業務板塊和地區（國家）分類的收入成長和預測分析
公司概況（策略、產品、財務資訊、關鍵趨勢等）

The organs-on-chip (OOC) market represents a frontier segment within biotechnology and life sciences tools, dedicated to the development and commercialization of microscale, bioengineered systems that emulate the structure and function of human organs. An organ-on-a-chip is a microfluidic cell culture device, typically no larger than a computer memory stick, that contains living human cells arranged to replicate key physiological aspects of a specific organ or tissue interface. By incorporating dynamic mechanical forces, fluid flow, and multi-cellular architectures, these platforms aim to create more predictive in vitro human models than traditional static cell cultures. This market is fundamentally driven by the quest for higher-fidelity human-relevant data in preclinical research.

Market expansion is fueled by critical needs within pharmaceutical R&D and a shifting scientific and ethical paradigm. The primary driver is the escalating demand for more predictive models in drug discovery and development. The persistent high failure rate of drug candidates in clinical trials, often due to a lack of efficacy or unforeseen toxicity not predicted by animal models, creates a powerful economic incentive for better preclinical tools. OOC platforms offer the potential to provide human-specific pharmacological and toxicological data earlier in the pipeline, thereby de-risking development. This is closely tied to the growing momentum toward personalized medicine, where patient-derived cells on chips could be used to stratify responders or test individualized treatment strategies. Furthermore, increasing ethical concerns and regulatory pressures to reduce, refine, and replace (3Rs) animal testing are accelerating the search for valid alternative methods, positioning OOC technology as a scientifically rigorous candidate.

The market's technological trajectory is defined by increasing biological complexity and functional integration. Innovation is progressing from single-organ chips toward interconnected multi-organ systems, or "body-on-a-chip" platforms, which aim to model systemic drug absorption, distribution, metabolism, and excretion (ADME) and organ-organ crosstalk. Concurrently, advancements are focused on enhancing the physiological relevance of individual chips through the incorporation of patient-derived iPSCs (induced pluripotent stem cells), immune system components, and more sophisticated microbiome interactions. This evolution from proof-of-concept to robust, standardized, and reproducible assay-ready platforms is central to achieving broader adoption.

The competitive and funding landscape is characterized by a vibrant ecosystem of specialized biotechnology startups, academic research spin-offs, and increasing engagement from large pharmaceutical companies. Collaboration is a dominant model, with pharma entities often forming research partnerships or licensing agreements with OOC developers to co-validate platforms for specific applications. Success for technology providers hinges on demonstrating clear, quantifiable value-such as the ability to replicate known human drug responses, predict clinical toxicity, or reduce assay time and cost compared to existing methods. Establishing standardized protocols and generating robust validation data against clinical outcomes are critical for transitioning from exploratory research tools to integrated components of the industrial R&D workflow.

Despite its transformative potential, the market faces substantial barriers to mainstream adoption. A foremost challenge is the inherent technical and biological complexity of faithfully mimicking human organ physiology in a microscale format. Reproducing the intricate cellular microenvironment, vascularization, and organ-specific mechanical cues remains a significant engineering and biological hurdle. This complexity directly contributes to the second major constraint: high cost. The development and use of advanced OOC platforms involve specialized equipment, consumables, and highly skilled personnel, creating a cost profile that must be justified by a demonstrable return on investment through reduced late-stage attrition. Finally, the path to regulatory acceptance for replacing established animal models in safety pharmacology is lengthy and requires the accumulation of extensive, compelling evidence to gain endorsement from agencies like the FDA and EMA.

In conclusion, the organs-on-chip market is a high-potential, innovation-driven sector at the intersection of biology, engineering, and data science. Its growth is conceptually supported by powerful economic and ethical drivers within pharmaceutical R&D. For industry experts, strategic focus must center on systematically validating these platforms against gold-standard clinical data to build confidence, driving down costs through scalable manufacturing and automation, and developing user-friendly, standardized systems that can be seamlessly integrated into existing industrial lab workflows. The ultimate measure of success will be the technology's proven ability to improve the predictability of drug development, thereby reducing costs, accelerating timelines, and delivering safer, more effective therapies to patients.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Organs on Chip Market Segmentation

By Offering
Products
Services
By Organ Type
Liver
Lungs
Kidney
Heart
Others
By Application
Drug Discovery
Regenerative Medicine
Disease Modeling
Others
By End-User
Pharmaceutical & Biotech Companies
Research & Academic Institutes
Others
By Geography
Americas
USA
Others
Europe Middle East and Africa
Germany
United Kingdom
Others
Asia Pacific
China
Japan
South Korea
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. ORGANS ON CHIP MARKET BY OFFERING

5.1. Introduction
5.2. Products
5.3. Services

6. ORGANS ON CHIP MARKET BY ORGAN TYPE

6.1. Introduction
6.2. Liver
6.3. Lungs
6.4. Kidney
6.5. Heart
6.6. Others

7. ORGANS ON CHIP MARKET BY APPLICATION

7.1. Introduction
7.2. Drug Discovery
7.3. Regenerative Medicine
7.4. Disease Modeling
7.5. Others

8. ORGANS ON CHIP MARKET BY END-USER

8.1. Introduction
8.2. Pharmaceutical & Biotech Companies
8.3. Research & Academic Institutes
8.4. Others

9. ORGANS ON CHIP MARKET BY GEOGRAPHY

9.1. Introduction
9.2. Americas
- 9.2.1. USA
- 9.2.2. Others
9.3. Europe Middle East and Africa
- 9.3.1. Germany
- 9.3.2. United Kingdom
- 9.3.3. Others
9.4. Asia Pacific
- 9.4.1. China
- 9.4.2. Japan
- 9.4.3. South Korea
- 9.4.4. Others